AstraZeneca (AZN.L) and Daiichi Sankyo (4568.T) on Friday secured U.S. approval that broadens the use of their therapy Enhertu, for patients with Breast Cancer, and paves the way for billions in sales. This is the first-ever U.S. Food and Drug Administration (FDA) approval for a medicine specifically targeting patients with so-called HER2-low breast cancer, the agency said. Breast cancer […]

The post AstraZeneca’s Enhertu wins keenly-anticipated U.S. breast cancer nod first appeared on World Pharma Today.